Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients - 05/01/13

Doi : 10.1016/j.diii.2012.05.001

L. Vadot ^a,^⁎ , M. Boulin ^a,^b, C. Malbranche ^a, B. Guiu ^c,^d, S. Aho ^e, A. Musat ^f, C. Pernot ^a, M.H. Guignard ^a, P. Hillon ^d,^g, P. Fagnoni ^a,^b
^a Pôle Pharmacie, CHU de Dijon, Bocage Central, 14, rue Gaffarel, 21000 Dijon, France
^b EA Inserm 4184, Université de Bourgogne, 7, boulevard Jeanne-d’Arc, 21000 Dijon, France
^c Department of Radiology, CHU de Dijon, Bocage Central, 14, rue Gaffarel, 21000 Dijon, France
^d Inserm U866, Université de Bourgogne, 7, boulevard Jeanne-d’Arc, 21000 Dijon, France
^e Department of Hospital Hygiene and Epidemiology, CHU de Dijon, Hôpital d’Enfants, 14, rue Gaffarel, 21000 Dijon, France
^f Medical Information Department, CHU de Dijon, Bocage Central, 14, rue Gaffarel, 21000 Dijon, France
^g Department of Hepatogastroenterology, CHU de Dijon, Bocage Central, 14, rue Gaffarel, 21000 Dijon, France

Corresponding author.

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Purpose

The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC).

Patients and methods

This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session.

Results

Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181days and 295days, respectively. Toxicity caused treatment discontinuation in three patients (14%). For the hospital, the average direct cost of treatment was €6,033 according to the analytical accounting system vs. €4,558 according to the official tariffs from the new French Diagnosis-Related Group prospective payment system (P=0.002).

Conclusion

In the treatment of HCC, on-demand DEB-TACE stabilises the disease in some patients but has not yet been thoroughly evaluated.

Le texte complet de cet article est disponible en PDF.

Keywords : Hepatocellular carcinoma, Transarterial chemoembolisation, Drug eluting beads, Result, Cost

Plan

Baseline characteristics of the patients

Disclosure of interest

Export

Vol 94 - N° 1

P. 53-59 - janvier 2013 Retour au numéro

Article précédent

Posterior reversible encephalopathy syndrome (PRES): Features on CT and MR imaging
E. Hugonnet, D. Da Ines, H. Boby, B. Claise, V. Petitcolin, V. Lannareix, J.-M. Garcier

| Article suivant

Value of transrectal power Doppler sonography in the detection of low-risk prostate cancers
J.-L. Sauvain, E. Sauvain, P. Rohmer, D. Louis, N. Nader, R. Papavero, J.-M. Bremon, J. Jehl

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients - 05/01/13

Abstract

Purpose

Patients and methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL